PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY

• Seok-Goo Cho,
• Tae Min Kim,
• Michał Taszner,
• Tsai Yun Chen,
• Aafia Chaudhry,
• Melanie Ufkin,
• Amulya Uppala,
• Ayesha Sabir,
• Hesham Mohamed,
• Srikanth Ambati,
• Emmanuel Bachy

Affiliations

Seok-Goo Cho

1 Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Rep. of South

Tae Min Kim

2 Seoul National University Hospital, Seoul, Korea, Rep. of South

Michał Taszner

3 Medical University of Gdańsk, Department of Haematology and Transplantology, Faculty of Medicine, Gdańsk, Poland

Tsai Yun Chen

4 National Cheng Kung University Hospital, Department of Internal Medicine, Tainan, Taiwan

Aafia Chaudhry

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Melanie Ufkin

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Amulya Uppala

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Ayesha Sabir

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Hesham Mohamed

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Srikanth Ambati

5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Emmanuel Bachy

6 Lyon Sud Hospital, Department of Hematology, Lyon, France